产品
编 号：F327518
分子式：C7H11NO4
分子量：173.17
分子式：C7H11NO4
分子量：173.17
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
1g
100
In-stock
5g
200
In-stock
10g
320
In-stock
25g
600
In-stock
结构图
CAS No: 33996-33-7
产品详情
生物活性：
Oxaceprol (N-Acetyl-L-hydroxyproline), an orally active derivative of L-proline, possesses distinct anti-inflammatory activity. Oxaceprol is usually used for the research of osteoarthritis and rheumatoid arthritis.
体内研究：
Oxaceprol, at 6 mg/kg/day for 7 days, significantly reduces both the surface area and wet weight of cotton pellet granulomas, being slightly less effective than indomethacin, 3 mg/kg.Oxaceprol (6–54 mg/kg/day) given therapeutically had no effect on the primary paw oedema response, but inhibits secondary lesions in the ears and tail.Oxaceprol does not inhibit the synthesis of prostaglandins in vitro, but markedly inhibits neutrophil infiltration into the joints of rats with adjuvant arthritis.Animal Model:Male Sprague-Dawley rats.
Dosage:18, 50 or 150 mg/kg.
Administration:Gavage daily for 15 days.
Result:Produced comparable inhibition of hyperalgesia to that produced by indomethacin.
Oxaceprol (N-Acetyl-L-hydroxyproline), an orally active derivative of L-proline, possesses distinct anti-inflammatory activity. Oxaceprol is usually used for the research of osteoarthritis and rheumatoid arthritis.
体内研究：
Oxaceprol, at 6 mg/kg/day for 7 days, significantly reduces both the surface area and wet weight of cotton pellet granulomas, being slightly less effective than indomethacin, 3 mg/kg.Oxaceprol (6–54 mg/kg/day) given therapeutically had no effect on the primary paw oedema response, but inhibits secondary lesions in the ears and tail.Oxaceprol does not inhibit the synthesis of prostaglandins in vitro, but markedly inhibits neutrophil infiltration into the joints of rats with adjuvant arthritis.Animal Model:Male Sprague-Dawley rats.
Dosage:18, 50 or 150 mg/kg.
Administration:Gavage daily for 15 days.
Result:Produced comparable inhibition of hyperalgesia to that produced by indomethacin.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备